Form 4: Sangamo Therapeutics Officer Reports Tax Withholding

Principal Accounting Officer Nikunj Jain reported the disposition of 1,919 shares to satisfy mandatory tax withholding obligations.

Summary

• Nikunj Jain, Principal Accounting Officer of Sangamo Therapeutics, Inc., disposed of 1,919 shares of common stock.
• The transaction occurred on May 25, 2026, at a price of $0.1743 per share.
• The disposition was non-discretionary, executed solely to satisfy mandatory tax withholding requirements related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 235,292 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing, as the transaction was a mandatory tax event and not a discretionary market sale.

Positives

• The transaction was a mandatory tax withholding event rather than a discretionary sale, indicating no change in the officer's long-term investment outlook.

Negatives

• The transaction reflects a low share price of $0.1743, highlighting ongoing valuation pressure for the issuer.

Risks

• Continued reliance on equity-based compensation in a low-share-price environment may lead to further dilution or tax-related share dispositions.

Future Outlook

The filing notes that 32,633 shares from the February 25, 2025 RSU grant remain to be vested in 7 successive equal quarterly installments, subject to continuous service.

Management Comments

• The transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that mandatory tax withholding filings are routine administrative events for biotech executives and do not typically signal a change in corporate strategy or insider sentiment regarding company performance.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions for tax obligations is standard practice for executive compensation plans across the biotechnology sector.
• The share price of $0.1743 reflects the significant market challenges faced by small-cap clinical-stage biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Next Steps

• Future vesting of remaining 32,633 shares in 7 successive equal quarterly installments.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Tax Withholding, Biotech